Visit the Website for Patients 
Français
Subscribe to our newsletter!
Follow the latest news from CATALIS and Clinical Trials Quebec
Approval Performances
21466 (Fiore)
Cardiology Phase III
- 8 weeks
- 1st site activated worldwide
BANTAM-01
Hepatocellular Carcinoma Phase I
- 13 weeks
- 1st site activated worldwide
BANTAM-01
Hepatocellular Carcinoma Phase I
- 12.8 weeks
- 1st site activated worldwide and FPI globally
BANTAM-01
Hepatocellular Carcinoma Phase I
- 15.2 weeks
- 2nd site activated worldwide
BO45853 (NeoTOV)
Breast Cancer Phase II
- 10.8 weeks
- 2nd site activated worldwide and FPI globally
BO45853 (NeoTOV)
Breast Cancer Phase II
- 9 weeks
- 1st site activated worldwide
BO45853 (NeoTOV)
Breast Cancer Phase II
- 8.6 weeks
- 3rd site activated worldwide
CEDK060A12101
Charcot-Marie Tooth Type 1A (CMT1A) Phase I
- 9.6 weeks
- FPI globally
CEDK060A12101
Charcot-Marie Tooth Type 1A (CMT1A) Phase I
- 6.6 weeks
- 2nd patient enrolled worldwide
CPKN605A12201
Atrial Fibrillation Burden Phase IIa
- 10.8 weeks
- FPI globally
CPKN605A12201
Atrial Fibrillation Burden Phase IIa
- 10.6 weeks
CPKN605A12201
Atrial Fibrillation Burden Phase IIa
- 9.4 weeks
CPKN605A12201
Atrial Fibrillation Burden Phase IIa
- 12 weeks
CPKN605A12201
Atrial Fibrillation Burden Phase IIa
- 13.6 weeks
ARTEMIDE-Lung03
Lung Cancer Phase III
- 8 weeks
- 2nd site activated worldwide and FPI globally
PAnTHA-PSMA Trillium
Prostate Cancer Phase I
- 10.4 weeks
- 1st site activated worldwide and FPI globally
PAnTHA-PSMA Trillium
Prostate Cancer Phase I
- 5.4 weeks
PAnTHA-PSMA Trillium
Prostate Cancer Phase I
- 19.2 weeks
PSMA-DC
Prostate Cancer Phase III
- 9.4 weeks
- 1st site activated in Canada and FPI globally
PSMA-DC
Prostate Cancer Phase III
- 8.8 weeks
- 2nd site activated in Canada
PSMACare
Prostate Cancer Phase II
- 9 weeks
- 1st site activated in Canada and FPI globally
PSMACare
Prostate Cancer Phase II
- 8.8 weeks
- 2nd site activated in Canada
CO44657 (pionERA)
Breast Cancer Phase III
- 10.2 weeks
- 3rd site activated in Canada - 4th site activated worldwide - 1st and 2nd patient enrolled globally
CO44657 (pionERA)
Breast Cancer Phase III
- 8.8 weeks
CO44657 (pionERA)
Breast Cancer Phase III
- 9 weeks
- 4th site activated in Canada - 5th site activated worldwide and 3rd patient enrolled worldwide
CO44657 (pionERA)
Breast Cancer Phase III
- 12.6 weeks
CO44657 (pionERA)
Breast Cancer Phase III
- 15.6 weeks
Galaxies 202
Head and Neck Cancer Phase II
- 8.8 weeks
- 1st site activated worldwide
SIRIUS-SLE1
Lupus Phase III
- 7 weeks
- 1st site activated worldwide and second patient enrolled globally